Xuanzhu Biopharmaceutical (2575 HK)

Xuanzhu Biopharmaceutical is an innovation-driven biopharmaceutical company in China, specializing in the development, industrialization, and commercialization of small-molecule and macromolecular drugs. The company focuses on major therapeutic areas including digestive diseases, oncology, and non-alcoholic steatohepatitis (NASH), with key products like KBP-3571, XZP-3287, and XZP-3621. It is headquartered in Beijing, China, and was founded in 2002.